Who makes S-Ibuprofen Topical Gel 5%?

S-Ibuprofen Topical Gel 5% is developed by Aponia Laboratories, Inc..

What development phase is S-Ibuprofen Topical Gel 5% in?

S-Ibuprofen Topical Gel 5% is in Phase 2.

Last reviewed 2026-05-14 · How we verify

S-Ibuprofen Topical Gel 5%

Aponia Laboratories, Inc. · Phase 2 active Small molecule

At a glance

Generic name	S-Ibuprofen Topical Gel 5%
Also known as	Active Gel
Sponsor	Aponia Laboratories, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS (PHASE2)
Phase II Study of AP0302 5% Versus a Vehicle Comparator (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

S-Ibuprofen Topical Gel 5% CI brief — competitive landscape report
S-Ibuprofen Topical Gel 5% updates RSS · CI watch RSS
Aponia Laboratories, Inc. portfolio CI